Article
Clinical Neurology
Alexander P. Murphy, Anna Johnson, Volker Straub, Alison Heads-Baister, Stephen Lord, John P. Bourke
Summary: The study aimed to audit the change in measures of left ventricular function in DMD patients before and after ACEi/BB therapy, showing a slower decline in left ventricular function after therapy initiation, supporting the international DMD recommendations.
Review
Pharmacology & Pharmacy
Lukasz Wolowiec, Grzegorz Grzesk, Joanna Osiak, Aleksandra Wijata, Martyna Medlewska, Patryk Gaborek, Joanna Banach, Anna Wolowiec, Mariola Glowacka
Summary: Beta-blockers are a diverse group of antiarrhythmic drugs that have different pharmacokinetic and chemical properties. Some selectively block beta-adrenergic receptors while others are non-selective. They reduce the influence of the sympathetic nervous system on the heart, resulting in negative effects on inotropy, chronotropy, bathmotropy, and dromotropy. Despite being used in medicine since the 1960s, they still play a crucial role in the treatment of cardiac arrhythmias. Propranolol, the oldest beta-adrenergic antagonist, has additional applications due to its unique properties.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Essraa Bayoumi, Phillip H. Lam, Robert Enders, Cherinne Arundel, Helen M. Sheriff, Vijaywant Brar, Corrine Y. Jurgens, Prakash Deedwania, Charles Faselis, Richard M. Allman, Gregg C. Fonarow, Ali Ahmed
Summary: This study found that the use of beta-blockers in older patients with HFrEF is associated with a lower risk of all-cause mortality, but not with a lower risk of heart failure readmission. This association is similar for patients admitted from nursing homes and those not admitted.
AMERICAN JOURNAL OF MEDICINE
(2022)
Article
Biology
Igor Diemberger, Alberto Spadotto, Giulia Massaro, Martina Amadori, Liviu Damaschin, Cristian Martignani, Matteo Ziacchi, Mauro Biffi, Nazzareno Galie, Giuseppe Boriani
Summary: Recent guidelines on atrial fibrillation (AF) introduced changes in rate control options, including combining beta-blockers and non-dihydropyridine calcium channel blockers. This study aimed to explore the prognostic impact of patient-specific rate control therapy compared to standard treatment. The analysis of 1112 patients showed no difference in one-year survival between the two groups. The use of non-dihydropyridine calcium channel blockers, alone or in combination with beta-blockers, showed clinical benefit in selected patients with heart failure.
Article
Cardiac & Cardiovascular Systems
Chan Soon Park, Jin Joo Park, Alexandre Mebazaa, Hae-Young Lee, Kye Hun Kim, Byung-Su Yoo, Seok-Min Kang, Sang Hong Baek, Eun-Seok Jeon, Jae-Joong Kim, Myeong-Chan Cho, Shung Chull Chae, Byung-Hee Oh, Dong-Ju Choi
Summary: The study investigated the impact of beta-blockers based on NP levels and HF phenotypes. Results showed that beta-blockers benefit HFrEF patients in terms of survival, have no effect on HFmrEF patients, and reduce mortality in HFpEF patients with high NP levels.
CLINICAL RESEARCH IN CARDIOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Alexander Bolton, Bishow Paudel, Mehul Adhaduk, Mohammed Alsuhaibani, Riley Samuelson, Marin L. Schweizer, Denice Hodgson-Zingman
Summary: This study examined the efficacy of intravenous diltiazem and metoprolol in controlling heart rate in patients with atrial fibrillation and/or atrial flutter with rapid ventricular response. The results showed that intravenous diltiazem was more effective than metoprolol in randomized trials, but no significant difference was observed in observational studies.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
(2023)
Review
Cardiac & Cardiovascular Systems
Giuseppe Boriani, Roberto De Ponti, Federico Guerra, Pietro Palmisano, Gabriele Zanotto, Antonio D'Onofrio, Renato Pietro Ricci
Summary: Effective drug and device therapy can reduce the occurrence of heart failure worsening and SCD in heart failure patients, with the added benefit of positive cardiac remodeling.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Public, Environmental & Occupational Health
In-Sun Oh, Yeon-Hee Baek, Han Eol Jeong, Kristian B. Filion, Ju-Young Shin
Summary: This study aimed to compare the ability of different methodological approaches to minimize immeasurable time bias in pharmacoepidemiological studies, specifically looking at the use of beta-blockers and all-cause mortality in heart failure patients. The results showed that adjusting for hospitalization as a time-varying variable successfully minimized the bias.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Giacomo Tini, Francesco Cappelli, Elena Biagini, Beatrice Musumeci, Marco Merlo, Lia Crotti, Matteo Cameli, Gianluca Di Bella, Alberto Cipriani, Francesca Marzo, Federico Guerra, Cinzia Forleo, Christian Gagliardi, Mattia Zampieri, Samuela Carigi, Pier Filippo Vianello, Giulia Elena Mandoli, Giuseppe Ciliberti, Luca Lichelli, Davide Mariani, Aldostefano Porcari, Domitilla Russo, Roberto Licordari, Alberto Ponziani, Italo Porto, Federico Perfetto, Camillo Autore, Claudio Rapezzi, Giafranco Sinagra, Marco Canepa
Summary: The use of beta-blockers in patients with cardiac amyloidosis is not uncommon, especially for the treatment of complications such as atrial fibrillation. Approximately 19% of patients had beta-blocker therapy withdrawn at the first evaluation, primarily due to intolerance in the presence of heart failure with advanced diastolic dysfunction.
Article
Cardiac & Cardiovascular Systems
Liyew Desta, Masih Khedri, Tomas Jernberg, Pontus Andel, Moman Aladdin Mohammad, Claes Hofman-Bang, David Erlinge, Jonas Spaak, Hans Persson
Summary: This study aimed to investigate the relationship between adherence to beta-blocker treatment after a first acute myocardial infarction (AMI) and long-term risk of heart failure (HF) and death. It found that nearly one in three AMI patients did not adhere to beta-blockers within the first year, and adherence was associated with improved long-term outcomes. However, uncertainty remains for patients with HFNEF and NEF.
Article
Cardiac & Cardiovascular Systems
Alireza Oraii, Jeff S. Healey, Alexander P. Benz, Arjun K. Pandey, Jorge A. Wong, Sylvanus Fonguh, Jia Wang, David Conen, Hertzel C. Gerstein, Stuart J. Connolly, William F. McIntyre
Summary: Most patients with atrial fibrillation do not have indications for SGLT2 inhibitors, but they still have a substantial risk of cardiovascular events. Future research should evaluate the efficacy of SGLT2 inhibitors in patients with atrial fibrillation.
CANADIAN JOURNAL OF CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Sebastian Wolfrum, Kevin Roedl, Alexia Hanebutte, Rudiger Pfeifer, Volkhard Kurowski, Reimer Riessen, Anne Daubmann, Stephan Braune, Gerold Soffker, Eric Bibiza-Freiwald, Karl Wegscheider, Heribert Schunkert, Holger Thiele, Stefan Kluge
Summary: This study found that hypothermic temperature control after IHCA did not improve survival nor functional outcome. The study may have been underpowered to detect clinically important differences between hypothermic temperature control and normothermia.
Review
Medicine, General & Internal
Gad Cotter, Beth A. Davison, Alexandre Mebazaa, Koji Takagi, Maria Novosadova, Yonathan Freund, Alain Cohen-Solal
Summary: There are multiple medication options for patients with heart failure and reduced ejection fraction, with RAASbs and BBs being the cornerstone of treatment. ARNis have shown to further reduce adverse effects, while other medications can be considered as adjunct therapies for symptom relief. Comparing the efficacy of these medications and prioritizing certain ones over others is important due to their similar side effects.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Teja Chakrala, Roshni O. Prakash, Anshul Jain, R. Ashton Vautier, Sahil Prasada, Mohammed Al-Ani, Mustafa M. Ahmed
Summary: This case report describes a 70-year-old woman with cardiac sarcoidosis who presented with non-ST elevation myocardial infarction, congestive hepatopathy, and acute renal failure. The patient required aggressive management strategies, including diuresis, intra-aortic balloon pump placement, inotropic and vasopressor support. Cardiac magnetic resonance imaging confirmed the diagnosis, and immunosuppressive therapy led to clinical improvement.
BMC CARDIOVASCULAR DISORDERS
(2023)
Article
Cardiac & Cardiovascular Systems
Vasiliki Bistola, Panagiotis Simitsis, John Parissis, Wouter Ouwerkerk, Dirk J. van Veldhuisen, John G. Cleland, Stefan D. Anker, Nilesh J. Samani, Marco Metra, Faiez Zannad, Eftihia Polyzogopoulou, Kalliopi Keramida, Dimitrios Farmakis, Adriaan A. Voors, Gerasimos Filippatos
Summary: After recent worsening of HF, up-titration of RASi and BBs was associated with a better prognosis in patients with LVEF <= 49%. Up-titration of BBs was associated with a greater risk of HF hospitalization when LVEF was >= 50%.
EUROPEAN JOURNAL OF HEART FAILURE
(2021)